Biodexa Pharmaceticals Stock Debt To Equity

BDRX Stock

4.98 0.41 8.97%

Biodexa Pharmaceticals fundamentals help investors to digest information that contributes to Biodexa Pharmaceticals' financial success or failures. It also enables traders to predict the movement of Biodexa Stock. The fundamental analysis module provides a way to measure Biodexa Pharmaceticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biodexa Pharmaceticals stock.

		Last Reported	Projected for Next Year
	Debt To Equity	0.02	0.02

Debt To Equity is likely to drop to 0.02 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Biodexa Pharmaceticals Company Debt To Equity Analysis

Biodexa Pharmaceticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Current Biodexa Pharmaceticals Debt To Equity

0.0174

Most of Biodexa Pharmaceticals' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biodexa Pharmaceticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Biodexa Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Biodexa Pharmaceticals is extremely important. It helps to project a fair market value of Biodexa Stock properly, considering its historical fundamentals such as Debt To Equity. Since Biodexa Pharmaceticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Biodexa Pharmaceticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Biodexa Pharmaceticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Intangible Assets	Net Receivables	Short Term Debt	Common Stock	Net Tangible Assets	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Property Plant Equipment	Current Deferred Revenue
Total Assets		0.98	-0.73	0.1	0.67	0.71	0.89	0.94	0.66	-0.38	-0.25	-0.29	0.37	0.34	-0.25	0.23	0.36	-0.17
Total Stockholder Equity	0.98		-0.8	0.09	0.62	0.59	0.92	0.9	0.59	-0.43	-0.3	-0.27	0.35	0.33	-0.3	0.29	0.33	-0.25
Net Debt	-0.73	-0.8		-0.04	-0.29	-0.2	-0.94	-0.55	-0.24	0.4	0.14	0.08	-0.09	-0.08	0.14	-0.14	-0.05	0.06
Retained Earnings	0.1	0.09	-0.04		0.1	0.33	0.02	0.18	0.0	0.83	-0.69	-0.69	0.85	0.83	-0.68	0.63	0.82	-0.61
Accounts Payable	0.67	0.62	-0.29	0.1		0.73	0.52	0.64	0.42	-0.12	-0.35	-0.35	0.46	0.44	-0.35	0.33	0.45	-0.31
Total Liab	0.71	0.59	-0.2	0.33	0.73		0.4	0.79	0.68	0.06	-0.31	-0.38	0.53	0.49	-0.3	0.25	0.53	-0.19
Total Current Assets	0.89	0.92	-0.94	0.02	0.52	0.4		0.71	0.45	-0.45	-0.2	-0.18	0.21	0.18	-0.2	0.2	0.17	-0.12
Intangible Assets	0.94	0.9	-0.55	0.18	0.64	0.79	0.71		0.59	-0.3	-0.29	-0.32	0.44	0.42	-0.28	0.25	0.44	-0.22
Net Receivables	0.66	0.59	-0.24	0.0	0.42	0.68	0.45	0.59		-0.24	0.0	-0.05	0.16	0.14	0.0	-0.03	0.19	0.03
Short Term Debt	-0.38	-0.43	0.4	0.83	-0.12	0.06	-0.45	-0.3	-0.24		-0.43	-0.48	0.59	0.57	-0.42	0.37	0.58	-0.35
Common Stock	-0.25	-0.3	0.14	-0.69	-0.35	-0.31	-0.2	-0.29	0.0	-0.43		0.78	-0.8	-0.84	1.0	-0.96	-0.65	0.87
Net Tangible Assets	-0.29	-0.27	0.08	-0.69	-0.35	-0.38	-0.18	-0.32	-0.05	-0.48	0.78		-0.77	-0.89	0.78	-0.63	-0.61	0.69
Net Invested Capital	0.37	0.35	-0.09	0.85	0.46	0.53	0.21	0.44	0.16	0.59	-0.8	-0.77		0.94	-0.79	0.75	0.96	-0.64
Short Long Term Debt	0.34	0.33	-0.08	0.83	0.44	0.49	0.18	0.42	0.14	0.57	-0.84	-0.89	0.94		-0.83	0.71	0.85	-0.73
Capital Stock	-0.25	-0.3	0.14	-0.68	-0.35	-0.3	-0.2	-0.28	0.0	-0.42	1.0	0.78	-0.79	-0.83		-0.96	-0.64	0.87
Net Working Capital	0.23	0.29	-0.14	0.63	0.33	0.25	0.2	0.25	-0.03	0.37	-0.96	-0.63	0.75	0.71	-0.96		0.64	-0.84
Property Plant Equipment	0.36	0.33	-0.05	0.82	0.45	0.53	0.17	0.44	0.19	0.58	-0.65	-0.61	0.96	0.85	-0.64	0.64		-0.57
Current Deferred Revenue	-0.17	-0.25	0.06	-0.61	-0.31	-0.19	-0.12	-0.22	0.03	-0.35	0.87	0.69	-0.64	-0.73	0.87	-0.84	-0.57

Click cells to compare fundamentals

High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Competition

Predict Biodexa Pharmaceticals

Debt To Equity Over Time

Biodexa Total Stockholder Equity

Total Stockholder Equity

4.44 Million

At this time, Biodexa Pharmaceticals' Total Stockholder Equity is fairly stable compared to the past year.

Biodexa Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biodexa Pharmaceticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biodexa Pharmaceticals could also be used in its relative valuation, which is a method of valuing Biodexa Pharmaceticals by comparing valuation metrics of similar companies.

Biodexa Pharmaceticals is currently under evaluation in debt to equity category among its peers.

Biodexa Fundamentals

	Return On Equity	-0.97
	Return On Asset	-0.38
	Operating Margin	(79.31) %
	Current Valuation	(3.23 M)
	Shares Outstanding	580.84 K
	Shares Owned By Insiders	10.16 %
	Shares Owned By Institutions	37.51 %
	Number Of Shares Shorted	13.76 K
	Price To Book	0.24 X
	Price To Sales	31.98 X
	Revenue	381 K
	Gross Profit	(4.41 M)
	EBITDA	(7.16 M)
	Net Income	(7.08 M)
	Total Debt	464 K
	Book Value Per Share	24.07 X
	Cash Flow From Operations	(6.83 M)
	Short Ratio	0.03 X
	Earnings Per Share	(75.50) X
	Target Price	156.43
	Number Of Employees	21
	Beta	1.44
	Market Capitalization	2.65 M
	Total Asset	10.54 M
	Retained Earnings	(144.77 M)
	Working Capital	1.46 M
	Net Asset	10.54 M

About Biodexa Pharmaceticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Biodexa Pharmaceticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biodexa Pharmaceticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biodexa Pharmaceticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Biodexa Stock Analysis

When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC